Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 23 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Table of Contents
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded494    
    Comments [Add]    
    Cited by others 6    

Recommend this journal

Year : 2010  |  Volume : 52  |  Issue : 1  |  Page : 37-41

Do antipsychotics limit disability in schizophrenia? A naturalistic comparative study in the community

1 Department of Psychiatry, National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore, India
2 Manasa Nursing Home, Thirthahalli-577432, Shimoga District, Karnataka, India

Correspondence Address:
Jagadisha Thirthalli
Department of Psychiatry, NIMHANS, Bangalore - 560 029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5545.58893

Rights and Permissions

Background: Though antipsychotics are effective against symptoms of schizophrenia and prevent relapses, their effect on disability has not been studied in a comparative design. Aim: To compare disability of schizophrenia patients receiving continuous antipsychotic treatment with that of those not receiving or receiving irregular treatment in a rural community setting using a naturalistic comparative study design. Patients and Methods: Disability was assessed in 182 schizophrenia patients living in Thirthahalli Taluk of Shimoga District, Karnataka, using Indian Disability Evaluation and Assessment Scale (IDEAS). Fifty patients (27.5%) were receiving regular treatment in the previous 2 years and their disability was assessed for the period when they were on antipsychotics. The remaining 132 patients (72.5%) had off-antipsychotics periods in the previous 2 years and their disability was assessed for the period when they were off-antipsychotics. Results: Patients on antipsychotics had significantly less disability across all domains of disability and in total IDEAS scores. Multivariate regression analysis showed that treatment status predicted disability scores after controlling for the effects of the confounding factors. Different levels of exposure to antipsychotic treatment were associated with different levels of disability. Conclusions: Treatment with antipsychotics is associated with significantly less disability. There is an urgent need to bring schizophrenia patients under the umbrella of treatment.



Print this article         Email this article